GOG Foundation

GOG Foundation Overview

The GOG Foundation has one mission that is dedicated to transforming
the standard of care in gynecologic oncology.

350+ Clinical Trials

400+ Participating Sites

115000+ Patients

Groundbreaking research, sincere impact.

The GOG Foundation, Inc. (GOG Foundation) is a nonprofit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies, including cancers that arise from the ovaries, uterus, cervix, vagina, and vulva. Our institutions and investigators are essential contributors to advancements in treatment regimens, surgical procedures, quality of life analyses, and prevention knowledge. The results of GOG Foundation clinical trials have influenced the standard of care for numerous malignant gynecologic neoplasms.


Our Mission

The mission of the GOG Foundation is to conduct clinical and translational research that positively impacts patients through the prevention and treatment of gynecologic malignancies.

Our Vision

The vision of the GOG Foundation is to be the premier collaborative network for transformative research in gynecologic malignancies.

Critical to the mission

The GOG Continuing Medical Education (CME) Program is dedicated to enhancing the knowledge of physicians and other healthcare professionals focused on improving the lives of cancer patients.

The GOG Foundation disseminates the clinical implications of research findings to its participating investigators and other health-care professionals around the world, as well as to cancer survivors, their families, support groups, and advocates.

Learn More

Dr. Alvarez speaking in Philadelphia

Research Structure

The GOG Foundation is the home of GOG Partners and the NRG Oncology gynecologic program.

Supported by industry, GOG Partners has been structured to work directly with pharmaceutical organizations and operate clinical trials outside the National Cancer Institute (NCI) framework. By providing an alternative venue for patient accrual and site infrastructure support, GOG Partners has helped stabilize the national gynecologic clinical trials network.

Learn More about GOG Partners

The federally-funded NRG Oncology conducts gynecologic cancer trials sponsored by the NCI. The 501(c)(3) was formed by the Gynecologic Oncology Group (a predecessor to the GOG Foundation), the National Surgical Adjuvant Breast and Bowel Project, and the Radiation Therapy Oncology Group.

Learn More about NRG Oncology


Dr. Thomas Herzog


Dr. Thomas J. Herzog took office as The GOG Foundation, Inc. President on July 20, 2023. Dr. Herzog brings a comprehensive background in clinical trials, the integral business aspects and acumen to this important position. A practicing gynecologic oncologist and member of the Board of Directors of GOG-F, he has served as the Treasurer of GOG-F from 2014-2023 and prior to taking presidential office, served as Associate Director of the GOG Partners (GOG-P) program. He is currently Deputy Director of the University of Cincinnati Cancer Center and Paul & Carolyn Flory Professor in the department of Obstetrics and Gynecology at the University of Cincinnati.

Dr. Robert S. Mannel

Senior Vice President

Dr. Robert Mannel serves as Sr. Vice President of the GOG Foundation, as well as NRG Oncology Group Chair. He is the Rainbolt Family Endowed Chair in Cancer and Professor of Gynecologic Oncology in the Department of Obstetrics and Gynecology at the University of Oklahoma Health Sciences Center (OUHSC).

Executive Leadership

GOG Partners

Dr. Bradley Monk


Dr. Kathleen Moore

Associate Director

Dr. Larry J. Copeland

Immediate Past President

Dr. Robert Coleman

Special Advisor to the President

NRG Oncology

Dr. Carol Aghajanian

Gynecologic Cancer Committee Chair

Dr. Paul DiSilvestro

Gynecologic Cancer Committee Vice Chair

Ovarian Cancer Leadership

GOG Partners

Dr. David O'Malley

Ovarian Trial Advisor

NRG Oncology

Dr. Kathleen Moore

Ovarian Committee Chair

Dr. Joyce Liu

Ovarian Committee Vice Chair

Uterine Cancer Leadership

GOG Partners

Dr. Brian Slomovitz

Uterine Trial Advisor

NRG Oncology

Dr. Matthew Powell

Uterine Cancer Committee Chair

Dr. Ann Klopp

Uterine Cancer Committee Vice Chair

Cervix Cancer Leadership

GOG Partners

Dr. Leslie Randall

GOG Partners - Cervix Trial Advisor

NRG Oncology

Dr. Charles Leath

Cervix/Vulva Cancer Committee Chair

Dr. Jyoti Mayadev

Cervix/Vulva Cancer Committee Vice Chair

Dr. Dmitriy Zamarin

Cervix/Vulva Cancer Committee Vice Chair

Rare Tumor Leadership

NRG Oncology

Dr. Allan Covens

Rare Tumor Committee Chair

Dr. Jubilee Brown

Rare Tumor Committee Vice Chair

Developmental Therapeutics Leadership

NRG Oncology

Dr. Roisin O'Cearbhaill

Developmental Therapeutics Committee Chair

Dr. Floor Backes

Developmental Therapeutics Committee Vice Chair

Associate Clinical Trial Advisors

GOG Partners

Dr. Ramez Eskander

Dr. Bhavana Pothuri

Administrative Executives

Katie Campbell

Executive Director, GOG Partners, Clinical Trials Management

Jenna Cummins

Executive Director of Business Development

Michael Powers

General Counsel, The GOG Foundation, Inc.

Laura L. Reese

Executive Director, Operations

Mary C. Sharp

Chief Financial Officer



Over the course of 50 years, the GOG Foundation has evolved to become a leader among clinical trial groups studying gynecologic cancer.

The Gynecologic Oncology Group, the earliest version of today’s GOG Foundation, was founded in 1970 and housed within the American College of Obstetricians Gynecologists. It later became an independent nonprofit with the formation of a 501(c)(3), providing a corporate home for NCI-sponsored cooperative group clinical trials. Since then, the GOG developed into a large organization with a robust trial portfolio that enjoyed extensive support from the gynecologic cancer research community.

Starting with the present

“We are going to have a great new generation of researchers in GYN oncology that are instilled with a passion and commitment to their field and their patients. From that passion is where you are going to see the great discoveries.”


GOG-258 shows adjuvant chemo-radiation does not improve relapse free survival vs chemotherapy alone in women with stage III or IV endometrial cancer.


GOG-213 shows secondary cytoreduction did not improve overall survival in patients with recurrent platinum sensitive ovarian cancer treated with chemotherapy and bevacizumab.


Dr. Larry J. Copeland is elected President of the GOG Foundation.


GOG-240 shows improved survival when bevacizumab is added to chemotherapy for advanced cervical cancer.


The Gynecologic Oncology Group (GOG) is restructured into The GOG Foundation, Inc.


The GOG, in partnership with the National Surgical Adjuvant Breast and Bowel Project and the Radiation Therapy Oncology Group, forms a new 501(C)(3) after the National Clinical Trials Network is reorganized. This new entity, NRG Oncology Foundation, Inc., becomes the corporate home for NCI-funded trials.


GOG-0173 demonstrates that sentinel node biopsy is effective in select women with vulvar cancer.


GOG-0218 improves PFS when bevacizumab was added to frontline chemotherapy and continued as maintenance in patients with stage III/IV ovarian cancer.


The GOG grows to nearly 200 member institutions across the country.


GOG-0172 intraperitoneal chemotherapy improved PFS and OS in women with stage III optimally debulked ovarian cancer.


The Gynecologic Oncology Group is incorporated.

“The GOG has fundamentally set the standards for cervical cancer, endometrial cancer, ovarian cancer management, but it also is looking forward to where we want to be.”


Dr. Philip J. DiSaia elected as GOG Group Chair.


By the turn of the century, the GOG had grown within the Cancer Therapy Evaluation Program (CTEP) and NCI portfolio to become a significant contributor in defining the standard of care in gynecologic oncology.


NCI issues alert that chemo-radiation should be considered for all patients with cervical cancer based on findings from GOG-85 (collaboration with SWOG) and four other randomized trials.


GOG-111 is a landmark study that led to incorporation of taxanes into frontline chemotherapy for advanced ovarian cancer.


The GOG Quality of Life Committee was formed and Protocol 9102 was first protocol with a primary endpoint of patient-reported effects of chemotherapy, paving the way for GOG’s continued dedication to improving the quality of life for our patients.


Hoskins et al publish The Influence of Cytoreductive Surgery on recurrence-free interval and Survival in small volume Stage III Epithelial Ovarian Cancer based on secondary analysis of GOG Protocol 52.


Dr. Robert Park is elected Group Chairman.


GOG-33 leads to surgical staging of endometrial cancer.


The first clinical publication of the GOG, the preliminary results of Pilot 1, surgical staging of endometrial cancer. By the end of the decade, a total of 40 manuscripts would be published.


The GOG grows to 34 institutions, covering about 4,000 new invasive cancers a year, with 23 protocols activated.


The Gynecologic Oncology Group (GOG) is founded and housed within the American College of Obstetricians and Gynecologists.

For a more comprehensive review of GOG's history and research, download our book.